Use of a high-affinity peptide that aborts MHC-restricted cytotoxic T lymphocyte activity against multiple viruses in vitro and virus-induced immunopathologic disease in vivo.
Virology
; 256(2): 246-57, 1999 Apr 10.
Article
en En
| MEDLINE
| ID: mdl-10191190
ABSTRACT
Binding of a specific peptide(s) from a viral protein to major histocompatibility complex (MHC) class I molecules is a critical step in the activation of CD8(+) cytotoxic T lymphocytes (CTLs). Once activated, CTLs can cause lethal disease in an infected host, for example, by killing virus-containing ependymal and ventricular cells in the central nervous system or viral protein-expressing beta cells in the pancreatic islets of Langerhans. Here we describe the usage of a designed (not natural) high-affinity peptide to compete with viral peptide(s)-MHC binding. This peptide blocks virus-induced CTL-mediated disease both in the CNS and in the pancreatic islets in vivo. Further, the blocking peptide aborts MHC-restricted killing of target cells by CTLs generated to three separate viruses lymphocytic choriomeningitis virus, influenza virus, and simian virus 40.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Péptidos
/
Proteínas Virales
/
Linfocitos T Citotóxicos
/
Antígenos H-2
/
Complejo Mayor de Histocompatibilidad
Límite:
Animals
Idioma:
En
Revista:
Virology
Año:
1999
Tipo del documento:
Article
País de afiliación:
Estados Unidos